Apontis Pharma : Notes on data protection (9 2025 apontis pharma notes on data protection)

APONTIS PHARMA AG Annual General Meeting on 29 July 2025 Information on data protection

The Company processes the following categories of personal data of its shareholders and their proxies in the course of holding the Annual General Meeting: contact data (e.g. name or email address), information on the shares held by each individual shareholder (e.g. number of shares) and administrative data (e.g. the AGM ticket number, access ID and password for the password-protected Internet service). The processing of personal data in the context of the Annual General Meeting is based on Section 6 para. 1 lit. c of the General Data Protection Regulation ("GDPR"). According to this, processing of personal data is lawful if the processing is necessary for compliance with a legal obligation. The Company is legally obliged to invite its shareholders to participate in an Annual General Meeting and to enable them to exercise their shareholder rights. In order to comply with this obligation, the processing of the above categories of personal data is indispensable. Without providing their personal data, the Company's shareholders will not be able to register for and participate in the Annual General Meeting.

The Company is responsible for data processing. The contact details of the responsible person are: APONTIS PHARMA AG

Rolf-Schwarz-Schütte Platz 1

40789 Monheim (Germany)

Tel. [phone]

Fax [phone]

E-Mail: [e-mail]

As a matter of principle, personal data relating to the shareholders of the Company will not be disclosed to third parties. By way of exception, third parties are given access to this data if they have been commissioned by the Company to provide services in connection with the holding of the Annual General Meeting. These are typical AGM service providers such as AGM agencies, lawyers, or auditors. The service providers only receive personal data to the extent necessary for the provision of the service.

As part of the statutory right to inspect the list of attendees at the Annual General Meeting, other attendees, shareholders and shareholder representatives connected electronically to the meeting may inspect the data recorded in the list of attendees. Personal data is also published in connection with requests for additions to the agenda, countermotions, or nominations for election which require publication. The same applies to the disclosure of submitted comments pursuant to Section 118a para. 1 sentence 2 no. 6 of the German Stock Corporation Act (AktG).

The above data will be kept for up to 3 years (but not less than 2 years) after the end of the Annual General Meeting, depending on the individual case, and will then be deleted, unless further processing of the data is still required in the individual case to process applications, decisions or legal proceedings relating to the Annual General Meeting.

Shareholders have the right to receive information free of charge upon request about the personal data stored about them. In addition, shareholders have the right to have inaccurate data relating to them corrected, the right to request the restriction of processing of data that has been processed too extensively, and the right to have personal data that has been processed unlawfully or stored for too long deleted (insofar as this does not conflict with any legal obligation to retain data and no other reasons pursuant to Section 17 para. 3 GDPR). In addition, shareholders have the right to transfer all data they have provided to the Company in a common file format (right to "data portability"). To exercise their rights, it is sufficient for the respective shareholder to send an email to [e-mail].

In addition, shareholders also have the right to file a complaint with a data protection supervisory authority. You can reach the data protection officer of APONTIS PHARMA AG under the following contact details: APONTIS PHARMA AG

Data Protection Officer

Rolf-Schwarz-Schütte Platz 1

40789 Monheim (Germany)

Tel.: [phone]

Email: [e-mail]

Monheim am Rhein, June 2025 APONTIS PHARMA AG

The Management Board